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Abstract: The cell division cycle 25 (CDC25) phosphatases include CDC25A, CDC25B 
and CDC25C. These three molecules are important regulators of several steps in the cell 
cycle, including the activation of various cyclin-dependent kinases (CDKs). CDC25s seem 
to have a role in the development of several human malignancies, including acute myeloid 
leukemia (AML); and CDC25 inhibition is therefore considered as a possible anticancer 
strategy. Firstly, upregulation of CDC25A can enhance cell proliferation and the 
expression seems to be controlled through PI3K-Akt-mTOR signaling, a pathway possibly 
mediating chemoresistance in human AML. Loss of CDC25A is also important for the cell 
cycle arrest caused by differentiation induction of malignant hematopoietic cells. Secondly, 
high CDC25B expression is associated with resistance against the antiproliferative effect of 
PI3K-Akt-mTOR inhibitors in primary human AML cells, and inhibition of this isoform 
seems to reduce AML cell line proliferation through effects on NFκB and p300. Finally, 
CDC25C seems important for the phenotype of AML cells at least for a subset of patients. 
Many of the identified CDC25 inhibitors show cross-reactivity among the three CDC25 
isoforms. Thus, by using such cross-reactive inhibitors it may become possible to inhibit 
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several molecular events in the regulation of cell cycle progression and even cytoplasmic 
signaling, including activation of several CDKs, through the use of a single drug. Such 
combined strategies will probably be an advantage in human cancer treatment.  
Keywords: CDC25; cell cycle; kinase; CDC25 inhibitors; anticancer agents; AML 
 
1. Introduction 
Reversible protein phosphorylation is an important molecular mechanism for the regulation of 
protein activity; this is true for many proteins that are essential for the regulation of important cellular 
events like intracellular signaling, cell cycle progression and proliferation, cellular differentiation and 
induction of apoptosis [1]. Protein phosphorylation and dephosphorylation are catalyzed by protein 
kinases and protein phosphatases, respectively [1]. The protein phosphatases can be divided into two 
different subclasses; the first class specifically hydrolyses serine/threonine phosphoesters whereas the 
second class is referred to as tyrosine phosphatases and specifically hydrolyses phosphotyrosine [2]. 
The tyrosine phosphatases also include a family of dual specificity phosphatases that hydrolyze both 
phosphotyrosines and serine/threonine phosphoesters; the cell division cycle 25 (CDC25) phosphatases 
are a subset among these dual specificity phosphatases [2]. This family includes CDC25A, CDC25B and 
CDC25C [3]; these three enzymes are important regulators of several steps in the cell cycle and they 
possibly have a role in the development of a variety of human malignancies [2,4]. CDC25 inhibition is 
therefore considered as a possible therapeutic strategy in cancer treatment.  
Cyclin-dependent kinases (CDKs) are important regulators of cell cycle progression, and CDK 
inhibition can be accomplished through inhibition of activating phosphatases [2]. Several CDKs are 
activated by CDC25A/B/C, and CDK inhibition can therefore be achieved through CDC25  
inhibition [2,5,6]. However, the CDC25s also have additional functions in cell cycle regulation, and 
several CDC25 inhibitors show cross-reactivity among the three CDC25 forms [2,5,6]. Thus, by using 
cross-reactive CDC25 inhibitors it will be possible to target several steps in cell cycle regulation, 
including several cyclin-dependent kinases, through the use of a single therapeutic agent.  
2. CDC25 and the Regulation of Cell Cycle Progression 
2.1. The Structure of CDC25 
CDC25 phosphatases are conserved eukaryotic proteins [7]. The three different human isoforms 
CDC25A/B/C contain 524, 580 and 473 amino acids, respectively, resulting in molecular masses in the 
53–65 kDa range [8]. The proteins consist of two domains: a highly conserved catalytic domain at the 
C-terminal and an N-terminal regularity region. The catalytic domain contains the HCX5R motif 
typically of tyrosine phosphatases [9]. The dipole moment of an adjacent α-helix favors the 
deprotonation of the catalytic cysteine increasing its reactivity towards phosphorylated threonine and 
tyrosine residues [10]. According to the crystal structures of human CDC25A and CDC25B [11,12], 
the isoforms differ in their amino acid arrangements around the catalytic site which supposedly is 
linked to divergences in specificity and activity [13]. As depicted in Figure 1, the two structures have 
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near identical folding in all conserved regions, with the only significant degeneration occurring in the 
extreme C-termini. Whereas the CDC25B C-terminal tail (residues 531–550) folds upon itself, perhaps 
to aid in substrate binding, the CDC25A tail (residues 484–495) is directed away from the active site, 
leaving it largely exposed. In contrast to other phosphatases, the active site of CDC25s is flat and 
shallow, suggesting a broad interaction interface. One of the largest cavities on the surface of CDC25B 
is adjacent to the catalytic pocket and is called the “swimming pool” because of the abundance of  
well-ordered water molecules it contains [14]. It seems as if substrate recognition relies on so-called 
hotspot residues (R488, R492 and Y497 on CDC25B) 20–30 Å apart from the active site [15]. Recent 
identification of a hotspot interaction between CDC25B and its native substrate, the CDK2/cyclin A 
complex, has moved some drug discovery attempts targeting CDC25B from the catalytic pocket to the 
remote hotspot region [16]. The regulatory domain at the N-terminal, on the other hand, contains 
several phosphorylation sites which regulate the activity and stability of the phosphatases, and their 
interaction with other proteins [17]. The domain also has signal peptides (nuclear localization 
sequence, NLS, and nuclear exportation sequence, NES) that determine the intracellular localization of 
the CDC25 proteins [18,19].  
Figure 1. Structures and domains of CDC25A and CDC25B. (A) Surface view of 
CDC25A (palegreen). The catalytic site is indicated in blue marine. The C-terminal tail 
(residues 484-495) is shown in palegreen cartoon. (B) Surface view of CDC25B (blue 
marine). The catalytic site and the adjacent “swimming pool” pocket are indicated in 
palegreen. The water molecules are represented as red spheres. The hotspot residues 
(R488, R492 and Y497), which govern the association with the protein substrate, are 
shown in blue sticks. The remote hotspot region is highlighted in palegreen. The α-helical 
C-terminal tail (residues 531–550) is shown in palegreen cartoon.  
 
2.2. CDC25 in Cell Cycle Regulation 
CDC25 phosphatases function as cell cycle regulators: they activate CDKs by dephosphorylating 
two residues within the ATP-binding loop [20]. The CDC25 isoforms fulfil different tasks throughout 
the cell cycle; this is also demonstrated by their localization as CDC25A predominantly is a nuclear 
(A) (B)
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protein [21] whereas the other two isoforms shuttle in and out the nucleus throughout cell cycle 
progression [22,23]. A simplified overview of the cell cycle regulation is shown in Figure 2. It is 
believed that all three isoforms are essential for the proper execution of the cell cycle, although it has 
been shown that CDC25A alone is sufficient for initiation of each step in the cycle [23,24]. 
Figure 2. An overview of the regulatory function of CDC25s in cell cycle progression. At 
G0-phase, cells that had been quiescent, re-enter the cell cycle after activation of 
CDK3/cyclin C. Dephosphorylation of CDK4/cyclin D, CDK6/cyclin D and CDK2 both in 
complex with cyclin E and cyclin A by CDC25s leads to the transition into the  
DNA-replication phase. At late S-phase, CDC25B activates CDK1/cyclin A. Finally, 
dephosphorylation of CDK1/cyclin B triggers mitotic entry, and in this important step all 
three CDC25 isoforms are involved. At the end of mitosis, both CDK1/cyclin B and the 
CDC25s are degraded and the cycle can start all over again. 
 
The CDK3/cyclin C complex initiates the re-entry of quiescent cells into the cell cycle from  
G0-phase. In middle G1-phase, CDC25A activates CDK4 and CDK6 that are in complex with  
cyclin D [25]. The latter at least partially inhibits retinoblastoma protein (Rb) in the G1/S-transition 
rate-limiting step [26], thus permitting transcription of genes that are required for cell cycle 
progression, including CDC25A and other cyclins [27,28]. CDC25A overexpression accelerates the 
entry into the DNA replication phase by dephosphorylation of CDK2/cyclin E, which additionally 
phosphorylates Rb [25] and mutually activates CDC25A in a feed-forward loop [21,29]. CDC25A 
reaches its highest expression level at late G1-phase, where it together with CDC25B facilitates the 
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transition into S-phase by dephosphorylation of CDK2/cyclin A, which in turn activates DNA 
replicating proteins [30]. CDC25C controls the initiation of the S-phase [31]. At late S-phase, 
CDC25B dephosphorylates CDK1/cyclin A, a less active complex compared to CDK2/cyclin A, which 
persists throughout G2-phase [30]. Dephosphorylation of CDK1/cyclin B by CDC25 is the rate-limiting 
step for the G2 to mitosis transition [32]. Active CDK1/cyclin B, that is inhibited by the Wee1 and 
Myt1 kinases [33], is the main trigger for mitosis. When CDK1 reaches a critical concentration level, it 
gets dephosphorylated by CDC25. At the same time, activated CDK1/cyclin B inactivates its inhibitor 
Wee1, thus resulting in an abrupt transition into mitosis [34]. All three CDC25 isoforms are involved 
in the G2/M-transition but CDC25B appears to take the key role in this process [35]. CDC25B is most 
abundant and active at late G2-phase and during mitosis, and is localized to the centrosome where it 
dephosphorylates CDK1/cyclin B [35,36]. The latter is subsequently translocated to the nucleus, where 
it is completely activated by CDC25C leading to mitotic onset [30]. CBC25B is then phosphorylated 
and this is supposed to be important for the regulation of the mitotic entry [37]. At the end of mitosis, 
both CDK1/cyclin B and the CDC25s are degraded resulting in transition into interphase. The proteins 
are subjected to anaphase promoting complex/cyclosome (APC/C)-dependent ubiquitination leading to 
proteasome-mediated degradation [38]. It also seems as if CDC25s can be inactivated by CDC14 family 
members that dephosphorylate the residues that previously had been phosphorylated by CDK1 [39]. 
Results from mice lacking CDC25B [40], CDC25C [22] or both [23] indicate that these proteins are 
not essential for cell cycle progression or for control of checkpoint responses. Additionally, 
concentration levels of CDC25A were not significantly altered in these models, suggesting that the 
third isoform does not compensate for the loss of the two others [23].  
2.3. Control of CDC25 Expression and Activity 
Because the CDC25s are essential for regulation of the cell cycle, their expression needs to be 
highly controlled. Dysregulation in the case of CDC25A, for example, accelerates the G1/S-phase 
transition [41], whereas an overexpression of CDC25B leads to premature mitotic entry [42]. The 
phosphatases are regulated both prior to transcription and post-translationally. At the transcription level, 
CDC25s are activated by the transcription factors E2F1, E2F2 and E2F3—the antagonists of Rb. Signal 
transducer and activator of transcription 3 (STAT3) usually activates CDC25 gene transcription, but 
through Rb recruitment it can also exhibit an inhibitory effect [43]. At the post-translational level, 
CDC25s are subject to protein modifications, both ubiquitination prior to degradation (described above) 
and phosphorylation. The latter is directed to mainly serines positioned in the N-terminal regulatory 
domain. Phosphorylation can either activate or inhibit the CDC25 phosphatases, leading to alterations 
in their catalytic activity, subcellular localization, substrate recognition and stability [17]. CDKs are 
the most important activators: CDK1/cyclin B mutually activates both CDC25B and CDC25C in a 
feed-forward loop resulting in mitotic entry, whereas CDK2/cyclin E and CDC25A form another  
feed-forward loop leading to DNA replication onset. Two other important kinases positively regulate 
CDC25s and promote mitosis: the polo-like kinase 1 (PLK1) and Aurora kinases. The former activates 
CDC25C both directly and indirectly by CDK1/cyclin B phosphorylation and inhibition of the Wee1-like 
kinase Myt1 [44], in addition to favoring the nuclear import of CDC25C [30,45], whereas the latter 
activates both PLK1 and CDC25s [46,47]. PLK1 also plays a role in mitotic exit, as it is a positive 
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regulator of the APC/C activity [48]. An overview of the most important activation and inhibition 
pathways is shown in Figure 3.  
Figure 3. Molecular interactions that regulate CDC25 activity (for simplicity reasons the 
effects of PI3K-Akt-mTOR signaling are described in the text but not included in the 
figure). The CDC25 activators are shown in red, the upstream inhibitors in blue and the 
downstream regulators in purple. Note that the CDC25s and the CDKs mutually activate 
each other. PLK1 is a key component as it positively regulates CDC25s and two of their 
activators, as well as it inhibits Myt1 and mediates the degradation of claspin. The key 
components for down-regulation of CDC25s are ATR and ATM. CDC25s are also prone to 
degradation by APC/C-dependent ubiquitination and nuclear exclusion by 14-3-3 binding. 
See text for further description.  
 
2.4. Cell Cycle Arrest and CDC25 Inhibition 
Cell cycle progression can be arrested at three stages: before entry into S-phase, during S-phase and 
prior to mitosis. At the G1/S checkpoint, DNA synthesis is inhibited, whereas intra-S phase arrest 
blocks mitotic entry until the S-phase is completed [30]. Finally, at the G2/M checkpoint, damaged cells 
are arrested in order to allow for cell repair or apoptosis [49]. CDC25s are inactivated by checkpoint 
kinases (CHK1 and CHK2) in an ataxia-telangiectasia mutated (ATM) and AT and Rad3-related (ATR) 
kinases-dependent manner. Upon DNA single-strand damage, ATR activates CHK1, whereas ATM 
activates CHK2 and the tumor suppressor protein p53 mainly as a result of double-strand breaks [45,50]. 
AP
C/
C
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Activated CHK1/CHK2 target CDC25 leading to its inhibition or degradation. The checkpoint kinases 
also increase the amount of Wee1 resulting in inactivation of CDKs [50], and the CDC25 activator 
PLK1 appears to be inhibited in an ATM/ATR-CHK1/CHK2-dependent manner. In detail, CHK2 
inhibits CDC25A through p53 [51] resulting in inactivation of CDK4/cyclin D and CDK2/cyclin E, 
thus blocking S-phase entry [51,52]. On the other hand, all three isoforms of CDC25 are 
phosphorylated by CHK1 in order to prevent mitotic onset. Phosphorylated CDC25A/B can no longer 
activate CDK1/cyclin B [53,54], and inactivation of CDC25B/C sequesters the proteins in the 
cytoplasm [37,55]. Also, hyperphosphorylation of CDC25A leads to its degradation [53,56]. The 
checkpoints are silenced after repair or degradation of the damaged cells [49], and the re-entry into 
mitosis upon DNA-damage arrest is controlled by CDC25B upon activation by PLK1 [57]. PLK1 also 
inactivates CHK1 by mediated degradation of Claspin, the adaptor and activating partner of CHK1 [58].  
In addition to the checkpoint kinases, several other proteins are involved in CDC25 inhibition, for 
example protein kinase B (PKB/Akt) and mitogen-activated protein kinases (MAPKs). The latter 
negatively regulate CDC25 upon DNA damage mediated by heat shock, oxidative stress, irradiation, 
feed deprivation and chemotherapy [30,59]. The effects of the PI3K-Akt-mTOR pathway on cell cycle 
progression are not completely understood and conflicting results have been obtained. On one side, 
Akt sequesters CDC25s in the cytoplasm upon binding to protein 14-3-3, thus inhibiting mitosis [60]. 
Also, it seems as if CDC25B activity itself is required for the activation of Akt and the p38 MAPK 
kinase [61], thus indicating a mutual regulation of these proteins. On the contrary, several studies have 
shown that Akt acts as an initiator of mitosis [62,63] and inactivation of both CHK1 [64] and CHK2 [65] 
by Akt have been observed, thus circumventing the degradation of CDC25s. Following DNA damage 
for instance, Akt impairs the activation of CHK1 in an ATR-independent manner, thus circumventing 
the cell cycle checkpoint and inhibiting apoptosis [66]. In concordance with this, inhibition of Akt led 
to restored CHK1 activity [67]. 
3. Small Molecule CDC25 Inhibitors 
Over the past few years, several synthetic and natural molecules with different structural features 
targeting CDC25 activity have been reported. Reviews by Lavecchia et al. provide a comprehensive 
overview of the current CDC25 inhibitor development [2,5,68,69]. The majority of the known CDC25 
inhibitors belong to various chemical classes including phosphate bioisosteres, electrophilic entities, and 
quinonoids. These compounds act via reversible inhibition with the active site of CDC25s [70–73], 
irreversible inhibition of CDC25s by electrophilic modification [74,75] or oxidation of the critical 
cysteine residue in the catalytic domain (HCX5R) by reactive oxygen species (ROS) generated in 
cultured cells treated with quinone derivatives [76,77]. This latter mechanism could be consistent with 
the non-selective inhibition of CDC25 isoforms by quinone-type inhibitors. Moreover, ROS may oxidize 
other phosphatases, as well as unrelated cysteine-based enzymes, and therefore quinone-containing 
agents could potentially trigger a range of unrelated events in cells. To date, many of the most potent 
CDC25 inhibitors are quinone-containing compounds which inhibit all three isoforms of CDC25 in an 
unselective manner (Figure 4). 
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Figure 4. Structures of the most active quinone-containing inhibitors of CDC25 phosphatases. 
 
• NSC95397, an unspecific naphthoquinone isoform shows IC50 values in the mid nM range [72], 
significantly inhibits the proliferation of human and murine carcinoma cells and blocks the G2/M 
phase transition of the cell cycle.  
• NSC 663284 is a potent, cell-permeable, and unspecific irreversible CDC25 inhibitor, arrests cells 
in the G1 and G2/M phases and induces significant growth inhibition of human breast cancer cell 
lines [75].  
• The quinone-based compound BN 82685 inhibits all three mammalian CDC25 phosphatases in the 
high nM range in biochemical assays (IC50 = 250, 250, and 170 nM, respectively) and blocks the 
growth of human pancreatic tumor Mia PaCa-2 cells xenografted into athymic nude mice [78]. BN 
82685 was further reported to retain its activity when taken orally. Furthermore, combining low 
concentrations of BN 82685 and paclitaxel (Taxol®), inhibits the proliferation of colon cancer  
cells [79], suggesting that combinations of CDC25 inhibitors with microtubule-targeting agents 
may be of therapeutic interest.  
• The bis-quinonoid IRC-083864 is the most potent CDC25 inhibitor described thus far with an IC50 
value of ~20 nM. It has activity in pancreatic and prostate cancer xenografts [80] and has entered 
into clinical trial under the name of Debio 0931, but no data are available yet. The two quinone 
groups of this large molecule are thought to deactivate the enzyme by covalent bond formation or 
oxidation of the critical active site thiolate anion.  
• Another CDC25 inhibitor, ARQ-501, entered phase I clinical trials in patients with advanced and 
chemotherapy-unresponsive solid tumors, and is undergoing a phase II trial in patients with 
leiomyosarcoma and head and neck cancer, having completed an additional trial in combination 
with the nucleoside analog gemcitabine [81,82]. It is probable, however, that ARQ-501 is not 
directly a CDC25 inhibitor, but rather functions by some other mechanism.  
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• Recently, Lavecchia et al. discovered a new quinonoid CDC25 inhibitor (NSC 119915) with 
micromolar activity by means of a structure-based high-throughput virtual screening [24]. 
Mechanistically, NSC 119915 displays irreversible inhibition kinetics with in vitro Ki values for 
CDC25A and CDC25B of 70 and 80 nM, respectively, generates intracellular ROS in cells, arrests 
cells in the G0/G1 and G2/M phase transitions of the cell cycle, and significantly suppresses the 
growth of human MCF-7 breast, PC-3 prostate, and K562 leukemia cancer cell lines.  
4. Biological Functions of CDC25 in Human AML 
Relatively few studies have investigated the role of CDC25 in human AML. The most important 
studies are presented in detail in Table 1 [49,83–91], but it should be emphasized that several of these 
studies are relatively small, describe observations mainly in AML cell lines or used methodological 
strategies that would not be regarded as optimal today. Thus, knowledge about CDC25 in human AML 
is in our opinion incomplete, but despite this CDC25 should be regarded as a possible therapeutic 
target in human AML. The following main observations have been made in the available studies with 
regard to the various CDC25 isoforms in human AML (Table 1). 
Table 1. The importance of CDC25 in AML; a summary of previous studies. 
CDC25 Isoform [Reference] 
Experimental Model 
Observations (Scientific Background, Observations, Conclusion) 
CDC25A [83] AML cell lines 
(KBM3/Bu250 and OCI-AML3) 
Background: The combination of fludarabine, clofarabine and busulfan has a cytotoxic effect on 
AML cells; the authors investigated the effect of adding the HDAC inhibitor suberoylanilide 
hydroxamic acid (SAHA) to the triple combination. 
Observations: 
1. HDAC inhibition increased the antiproliferative effect together with caspase activation and 
induction of apoptosis. 
2. Additional HDAC inhibition induced an ATM-initiated DNA damage response with activation of 
p53 and CHK2. 
3. The four-drug combination activated the ATM-CHK2-CDC25-CDK1 pathway with increased 
CHK2 phosphorylation, decreased CDC25A levels and thereby increased phosphorylation and 
deactivation of the downstream target CDK1. 
4. Similar observations could be seen in primary human AML cells (only 3 patients examined). 
Conclusion: Decreased CDC25A expression is seen in AML cells following exposure to 
antiproliferative and cytotoxic treatment. 
CDC25A [84] Various cell 
lines, including the HL60 AML 
cell line 
Background: The authors investigated the antiproliferative effects of extracts from the plant 
Acalypha alopecuroidea.  
Observations: 
1. The extract had an antiproliferative and cytotoxic effect. 
2. A DNA damage response was seen with CHK2 phosphorylation/activation subsequently leading 
to inactivation of CDC25A through phosphorylation and finally CDK1 Y15 hyperphosphorylation 
with cell cycle arrest. 
Conclusion: Antiproliferative and cytotoxic effects with cell cycle arrest are associated with 
CDC25A inactivation. 
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Table 1. Cont.  
CDC25 Isoform [Reference] 
Experimental Model 
Observations (Scientific Background, Observations, Conclusion) 
CDC25A [85] HL60 AML cells 
Background: The anticancer-effect of extracts from the plant Scutellaria orientalis was investigated. 
Observations: 
1. The extract had a dose-dependent proapoptotic effect and induced genotoxic stress. 
2. Dose-dependent p21 induction together with dose-dependent CDC25A/cyclin D1 downregulation 
was also observed. 
Conclusion: Genotoxic stress and antiproliferative/proapoptotic effects are associated with 
downregulation of CDC25A. 
CDC25A [86] Various cell 
lines, including AML lines 
Background: The PI3K-Akt-mTOR pathway can be constitutively activated in human AML cells; 
the authors investigated a possible functional link between this pathway and CDC25A expression. 
Observations:  
1. Alk-dependent proliferation was inhibited by RNA interference-mediated downregulation of 
CDC25A. 
2. Pharmacological CDC25 inhibition reduced ALK (anaplastic lymphoma kinase)-dependent 
proliferation.  
3. PI3K-Akt-CDC25 mediated intracellular signaling downstream to the FLT3 growth factor receptor. 
Conclusion: High CDC25 protein levels are important for PI3K-Akt-mediated growth enhancement. 
CDC25A [87] AML cell lines 
(KG1a, U937) 
Background: Interactions with the microenvironment are important for regulation of proliferation 
for many different cells. 
Observations: 
1. Adhesion to fibronectin increased AML cell proliferation through increased S-phase entry; 
differentiated normal progenitors showed a similar effect whereas normal CD34+ cells showed 
decreased proliferation. 
2. The AML cells showed accumulation of CDC25A; pharmacological inhibition or siRNA-mediated 
downregulation of CDC25A impaired adhesion-dependent proliferation. CDC25A accumulation was 
CDH1 dependent and due to modified proteasomal degradation. 
3. The adhesion-induced proliferation and CDC25A upregulation was mediated through activation of 
the PI3K-Akt-mTOR pathway. 
Conclusion: CDC25A upregulation can be mediated by integrin-initiated signaling through PI3K-
Akt-mTOR. 
CDC25B [88] AML cell lines 
but also an immature subset of 
primary human AML cells 
(CD34+, high aldehyde 
dehydrogenase activity) 
Background: The immediate-early response gene 5 (IER5) can function as a regulator of cell 
proliferation in cancer cells; the authors investigated whether IER5 is a regulator of AML cell 
proliferation. 
Observations: 
1. IER5 was constitutively expressed in human AML cells. 
2. Overexpression of IER5 caused a decrease in CDC25B associated with an antiproliferative effect 
and G2/M arrest. 
3. Downregulation of CDC25B mRNA expression was caused by IER5 binding to the promoter and 
mediated through NF-YB and p300. 
Conclusion: IER5-induced growth inhibition of immature AML cells is associated with 
downregulation of CDC25 expression. 
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Table 1. Cont. 
CDC25 Isoform [Reference] 
Experimental Model 
Observations (Scientific Background, Observations, Conclusion) 
CDC25B [49] AML cell 
lines (KG1a, U937) and 
primary human AML cells 
Background: The importance of the G2/M checkpoint for the sensitivity of AML cells to genotoxic 
stress was examined; exposure to etoposide was used as the genotoxic stress. 
Observations: 
1. G2/M checkpoint stringency varied between AML cell lines; U937 cells showed an earlier exit from 
the checkpoint than KG1a cells after exposure to etoposide. Etoposide caused increased 
phosphorylation/activation of CHK1 in both cell lines, but the earlier exit by U937 cells was associated 
with an earlier decrease in CHK1 activation. 
2. CDC25B protein levels increased after etoposide exposure. CDC25B is important for checkpoint 
recovery, and pharmacological as well as siRNA inhibition of CDC25B caused an inhibition of the 
checkpoint recovery and entry into mitosis. 
3. Combination of etoposide + CHK1 inhibition increased the number of mitotic and apoptotic cells. 
Increased cytotoxicity was also seen for primary AML cells when combining etoposide with CHK1 
inhibition, but this potentiating effect differed between patients. 
Conclusion: CDC25 is important for the sensitivity of human AML cells for genotoxic stress.  
CDC25B [89] Primary 
human AML cells 
Background: Is CDC25 important for the antiproliferative effect of PI3K/mTOR inhibitors in primary 
human AML cells? 
Observations: 
1. Resistance to PI3K/mTOR inhibition was associated with increased expression of CDC25B. 
2. Pharmacological CDC25 inhibition has an additive antiproliferative effect to PI3K/mTOR inhibition 
only for certain cell lines and for a subset of patients. 
Conclusion: The effect of CDC25 inhibition differs between patients, additive antiproliferative effects 
to PI3K-mTOR inhibition are seen only for a subset. 
CDC25C [90] AML cell line 
U937 
Background: Does CDC25C associate with cyclin A in human AML cells? 
Observations:  
CDC25C coprecipitated with cyclin A in proliferating cells, this was not seen after apoptosis induction 
through the extrinsic and intrinsic pathways. 
Conclusion: CDC25C contribute to cell cycle regulation in human AML cell lines through complexing 
with cyclin A.  
CDC25C [91] Primary 
human AML cells 
Background: Normal cells show different CDC25C splice variants, is this also true for primary human 
AML cells? 
Observations:  
Several splice variants were detected in primary human AML cells, and the splicing pattern differed 
between AML cells and normal CD34+ hematopoietic cells. 
Conclusion: Aberrant splicing may contribute to the AML cell phenotype and to functional differences 
in cell cycle regulation between patients.  
CDC25 inhibitors can inhibit AML cell proliferation induced by integrin adhesion to  
fibronectin [87]; this integrin-initiated growth enhancement seems to be at least partly mediated 
through activation of PI3K-Akt-mTOR signaling, and its inhibition is thus an additional observation 
suggesting a functional interaction between CDC25 and PI3K/Akt/mTOR. The importance of CDC25 
for Akt-dependent and integrin-initiated proliferation was described for the CDC25A isoform, whereas 
the other isoforms were not examined. However, most CDC25 inhibitors are not specific for CDC25 
isoforms, i.e., there are only quantitative but not qualitative differences in their activity with regard to 
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inhibition of CDC25A/B/C [2] and it cannot be excluded that other isoforms and not only CDC25A 
contribute to the inhibition of Akt-dependent proliferation caused by pharmacological CDC25 
inhibition. To conclude, our knowledge about CDC25 in human AML is incomplete and fragmentary 
but the observations so far suggest that there are functional interactions with both Aurora kinases, 
PLK1, NFκB and PI3K/Akt/mTOR; all these mediators are regarded as important for AML (stem) cell 
proliferation and survival. For this reason the possible role of CDC25s as potential therapeutic targets 
in human AML should be further investigated. 
• CDC25A. Upregulation of CDC25A enhances lymphoma cell proliferation [87]. Its expression 
seems to be controlled through PI3K-Akt-mTOR signaling [87]. Loss of CDC25A is also important 
for cell cycle arrest during the differentiation of malignant hematopoietic cells [92]. This isoform 
seems to be important for the DNA damage response during exposure of human AML cells to 
cytotoxic drugs. It also seems important for Akt-dependent proliferation in AML cells because 
inhibition or knock-down of CDC25A reduces the Akt-dependent AML cell proliferation. The 
FLT3 gene is frequently mutated and thereby encodes a constitutively activated kinase in human 
AML and is an adverse prognostic factor [93]; this FLT3-initiated signaling is mediated through 
different pathways (including PI3K-Akt-mTOR) and CDC25 may thereby mediate or contribute to 
the adverse prognostic impact of this genetic abnormality.  
• CDC25B. High expression is associated with resistance against the antiproliferative effect of  
PI3K-Akt-mTOR inhibitors [89], but the molecular mechanisms behind this effect are not known. 
Inhibition of this isoform seems to reduce AML cell line proliferation through effects on NF-YB 
and p300 [88]; whereas in other cells growth inhibition is seen only with combined Cyclin D1 and 
CDC25B inhibition [84]. These regulatory events thus represent a link between CDC25 and  
the NF-YB system that consist of the three subunits NF-YA, NF-YB and NF-YC; this system seems 
to contribute to carcinogenesis for several human malignancies [94]. Finally, activation of the 
NFκB system is also important for transcriptional regulation, and inhibition of NFκB at G2/M phase 
transition delays mitotic entry and inhibits transcription of G2/M-specific genes, including cyclin B, 
PLK1, and CDC25B [95]. NFκB is important for leukemic stem cell functions and their 
chemosensitivity [96], but it is not known whether this importance of NFκB on AML stem cells is 
mediated through its effects on CDC25B transcription. 
• CDC25C. The molecule is encoded on chromosome 5 and CDC25C seems important for the 
phenotype of AML cells with chromosomal deletions involving this chromosome [97]. Malignant 
myeloid cells seem to express a splicing/isoform profile of CDC25C that is different from normal 
hematopoietic cells [91].  
5. The Molecular Context of CDC25 in Human AML Cells 
Cell cycle progression is a multistep process regulated by an interacting molecular network, and the 
CDC25 family is important at different steps. However, the expression or function of several other 
regulators can also be altered in human AML; leukemia-associated alterations of other important 
regulators will be described below.  
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5.1. Regulation of the G1 Phase of the Cell Cycle in Human AML Cells 
Cells that have exited mitosis can become quiescent, differentiate or progress to another cell 
division cycle; initiation of a new cell cycle can be stimulated by the downstream signaling from 
various growth factor or cytokine receptors and at the same time the transcriptional regulation can be 
altered to suppress differentiation [98]. However, as summarized in Table 2, the various genetic 
abnormalities of the AML cells will differ in their effects on various regulators of G1/S-phase 
progression [98–108]. Regulation of the G1 phase thus seems to differ between patients according to 
their AML-associated genetic abnormalities. 
CDK2 and CDK4/6 activation in G1 can be caused by various molecular mechanisms and not only 
by CDC25, and several of these molecules are regarded as potential therapeutic targets in human 
malignancies. The optimal targeting of G1 progression is therefore likely to differ between patients, 
and the possible therapeutic strategies include p53 activation and inhibition of various receptor 
tyrosine kinases, CXCR4 and CDK4/6 [33,105,107,109,110].  
5.2. Regulation of the S-Phase  
The regulation of S-phase progression is summarized in Figure 2 and the altered regulation of this 
phase in human AML cells is described more in detail in Table 3 [49,98,99,102,111–129]. The 
regulation of S-phase progression can be altered in primary AML cells, and the alterations can be both 
upstream and downstream to CDC25. This cell cycle phase is targeted by the antileukemic drugs 
cytarabine, clofarabine and anthracyclines [130–133]. Finally, the histone modifier MLL is affected by 
the various 11q23-involving translocations; MLL functions as a cell cycle regulator through its effects 
on CDC45 and the function of CDC45 in cell cycle regulation seems to be altered especially in the 
patient subset with these translocations [102].  
5.3. Regulation of the G2 Phase  
Table 4 gives an overview of important regulators of the G2 phase that ends up with CDC25 
mediated activation of CDK1/cyclin B; the described abnormalities of G2 regulation in primary human 
AML cells are summarized in the table [95,127–129,134–140]. Similar to the G1 phase, the molecular 
context of CDC25 varies between patients also for this phase, but in contrast to the G1 phase where the 
heterogeneity is mainly due to the direct effects of AML-associated genetic abnormalities, the 
heterogeneity of G2 regulation is mainly determined by differences in expression levels (BRCA1, 
PP2A, PLK1, cyclin B) or isoform profiles (p53, PP2A).  
5.4. Regulation of Mitosis  
CDC25 is not an important mediator in regulation of the mitotic step that includes the spindle 
assembly checkpoint members together with the Aurora kinases and PLK1 [98]. However, several of 
these regulators can be altered in human AML, the most important being listed below: 
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Table 2. The molecular environment of CDC25—altered regulation of the G1 phase in human AML (← stimulation; ┴ inhibition). 
Signaling Cascade Effects on Cell Cycle Regulation—Effects of Genetic Abnormalities  
Receptor ligation 
or mutations 
↓ 
STATs 
MAP kinases 
PLC 
↓ 
CDK4/6 
Cyclin D 
↓ 
 
↓ 
 
CDK2 
Cyclin E 
 
↓ 
 
↓ 
 
Entering of  
S-phase 
 
 
←  RTK 
 
 
          ↓ 
 
 
←  PIM kinases 
 
          ┴ 
├    CKIs 
 
 
├  p53/p21 
← E2F 
 
 
 
 
 
 
 
 
Receptor ligation and mutations of growth factor receptor tyrosine kinases: Proliferation of primary AML cells is increased by 
receptor ligation [103]; receptor tyrosine kinase (RTK) mutations (e.g., c-kit mutations, FLT3-mutations) can cause constitutive 
signaling [98]. High CXCR4 levels is seen for a minority of patients and is associated with adverse prognosis [105]. 
CDK4/6: These mediators stimulate G1 progression and bind/sequester CDK inhibitors (CKI), e.g., p14, p16, p27 [98]. p14 and p27 
can show increased expression in AML, p16 may show low expression [106].  
PIM kinases: These kinases are activated by the upstream receptor ligation together with STAT/MAP kinases and thereafter 
increase CDK4 activation [98]. They also decrease the effects of the CKIs, and PIM1 activates CDC25 directly (see Table 4). 
CKI (CDK inhibitors): High p27 levels seem to be predictive of complete remission after intensive induction chemotherapy [102]. 
Phospholipase Cβ 1 (PLC): The nuclear form of this enzyme is an important checkpoint that controls progression through the G1 
phase, its activation depends on type 1 insulin-like receptor (IGF-R) and monoallelic deletions seem to be associated with 
aggressive disease both for patients with AML and patients with preleukemic myelodysplastic syndromes [108]. 
CDK2 activation: The upstream receptor-initiated signaling activates CDK2 through CDK4/6 dephosphorylation.  
Cyclin E: The expression varies between AML patients, high expression is seen in one third of the patients [99].  
p53 and p21—different p53 isoforms associated with FLT3-ITD and NPM1 mutations: p53 inhibits G1 progression through p2 
induction. p53 is mutated only in a minority of AML patients; but the balance between various isoforms differ between patients, 
e.g., between patients with adverse prognosis FLT3-ITD and NPM1 mutations [107]. 
E2F: Inactivation of the Rb gene by CDK4/6 releases the E2F transcription factor that increase transcription of cyclin E; aberrant 
expression of a variant E2F can be seen in human AML [100,101]. 
TET2 mutations: These loss-of-function mutations are detected in 10-20% of AML patients, loss of TET activity leads to increased 
proliferation and is associated with adverse prognosis [104]. 
MLL fusion proteins—11q23 translocations: The wild-type MLL protein cause histone methylation; its expression normally 
peaks at the G1/S boundary but the fusion protein shows stable expression and therefore seems to abrogate checkpoint control and 
increase the expression of homeobox transcription factors as described in detail by [98].  
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Table 3. The molecular environment of CDC25 during the S-phase of the cell cycle (← stimulation; ┴ inhibition). 
Signaling 
Pathway 
Additional 
Regulator 
Normal Molecular Function Abnormality in Human AML 
DNA damage 
Replication 
checkpoint 
↓ 
ATR 
↓ 
CHK1 
┴ 
CDC25 
Claspin 
ATR: a serine-threonine kinase activated by DNA damage [98]. 
Claspin: activated by ATR through phosphorylation, initiates 
DNA repair and enhances this DNA damage response through 
stimulation of CHK1 [120,123]. 
CHK1: a serine/threonine kinase that inhibits CDC25 through 
addition of inhibitory phosphate groups. Differentially expressed 
in AML cell lines [111]. 
Clinical relevance: MLL-fusion proteins caused by 11q23 
translocations can inhibit the MLL-ATR interaction, causing 
MLL degradation and continued replication [115]. 
ATR: stabilizes the chromatin-remodeller MLL (see below), this ability is lost for MLL-fusion 
proteins encoded by 11q23 translocations [98]. 
Claspin: differentially expressed in AML cell lines [49] 
CHK1: experimental and clinical studies suggest that CHK1 inhibition has antileukemic effects 
[112,114].  
Chemotherapy: cytarabine and clofarabine cause S-phase/replication arrest and CHK1 and 
CHK2-mediated inhibitory phosphorylation of CDC25 [98]. 
Double-strand 
break 
Intra-S phase 
Checkpoint 
↓ 
ATM 
↓ 
CHK2 
┴ 
CDC25 
RAD51C 
PIM kinase 1 
FLT3-ITD 
ATM: a serine/threonine kinase activated by DNA double 
strand breaks. 
CHK2: a serine/threonine kinase that adds inhibitory phosphate 
to CDC25 and thereby inhibits CDK2. 
RAD15C: Involved in ATM-dependent binding to DNA 
double-strand breaks required for CHK2 phosphorylation [122]. 
PIM kinase 1: this serine/threonine kinase transduces cytokine-
initiated mitogenic signals; it phosphorylates CDC25A directly 
and this phosphorylation increases the phosphatase activity of 
CDC25A [126]. 
ATM: genetic variants of ATM influence treatment outcome, heterozygous ATM 4138C>T is 
associated with an inferior treatment outcome after intensive chemotherapy [121]. Missense 
mutations have been detected in AML [118]. 
CHK2: can be mutated in human AML, but this is uncommon [111].  
RAD51C: polymorphisms do not influence risk of AML or outcome after chemotherapy [116]. 
FLT3-ITD: this is a common AML mutation associated with chemoresistance and reduced 
AML-free survival. It shows constitutive signaling and causes activation of CDC25. Normal 
myeloid differentiation requires activation of the transcription factor C/EBPα; constitutively 
activated FLT3-ITD causes an inhibitory phosphorylation and thereby a block of differentiation 
mediated either by ERK1/2 or by CDK1 (see description of the G2 phase, Table 4) [127–129]. 
Chemotherapy: topoisomerase inhibitors (etoposide, anthracyclines) favor DNA strand breaks 
and provoke a checkpoint response involving ATM [98]. 
CDC25 
↓ 
↓ 
CDK2 
Cyclin A 
Cyclin C 
↓ 
↓ 
CDC45 
 
CDK2: a serine/threonine kinase activated by cyclin A and 
cyclin C and inactivated by p21 and p27. 
Cyclin A: regulates S-phase progression, interact with  
c-Myb [113,117,124]. 
Cyclin E: regulates G1/S transition 
CDC45: regulator of replication, regulated by wild-type MLL 
[102]. 
p21: inhibitor of CDK2 and CDK4 
p27: inhibitor of CDK2 and CDK4 
CDK2: high activity with fast progression through S-phase has been described in AML [102]. 
Cyclin A: high activity with fast progression through S-phase has been described 
[113,117,124].  
Cyclin E: high activity with fast progression through S-phase has been described in human 
AML [99]. 
CDC45: altered regulation in 11q23 AML [102]. 
p21: deficiency cooperates in t(8;21) variants of AML [119]. 
p27: downregulated in AML, faster S-phase progression [125]. 
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Table 4. The molecular environment of CDC25‒altered regulation of the G2 checkpoint in human AML (← stimulation; ┴ inhibition). 
Signaling Cascade Effects on Cell Cycle Regulation—Effects of AML-Associated Abnormalities  
 
DNA-damage 
 
↓ 
 
ATR-ATM 
CHK1-CHK2 
 
┴ 
CDC25 
 
↓ 
 
CDK1 
Cyclin B 
 
↓ 
 
Mitosis 
 
γ-H2Ax, 
BRAC1 
 
SET  
┴ 
← PP2A 
 
 
 
← PLK1 
← 
FOXM1 
 
 
 
├ p53/p21 
NFκB and cell cycle regulation:  
Activation of the NFκB system is important for transcriptional regulation, and inhibition of NFκB delays mitotic entry and 
inhibits transcription of G2/M-specific genes, including cyclin B, PLK1, and CDC25B [95]. NFκB is important for AML 
stem cell functions and their chemosensitivity [96], but it is not known whether its effect on leukemic stem cells is mediated 
through altered CDC25B expression. 
The DNA damage response: 
γ-H2Ax: Phosphorylation of this histone is an indication of a DNA damage response, the AML cell level after treatment 
shows considerable variation between patients [135]. 
BRCA1/2: DNA repair is closely linked to cell cycle regulation; reduced BRCA1 gene expression is seen for a minority of 
de novo AML but for a majority of secondary AMLs [138]. 
SET: an endogenous inhibitor of PP2A [134].  
PP2A: Inactivation through phosphorylation is seen in primary AML cells for a majority of patients; this inactivation can be 
caused by either deregulated expression of endogenous PP2A inhibitors (e.g., SET, see above), overexpression of SETBP1 or 
downregulation of PP2A subunits [134].  
PLK1: This kinase is overexpressed in primary AML cells for a majority of patients [137,139]. 
FOXM1:  This transcription factor seems to be overexpressed in primary AML cells for most patients; decreased expression 
is associated with G2-arrest and reduced levels of Aurora kinase B, cyclin B1 and CDC25B together with increased levels of 
p21 and p27 at the protein level [136]. 
Cyclin B: Cyclin B1 is commonly expressed in primary AML cells, but the expression pattern (cytoplasmic versus nuclear) 
varies between patients [140]. The expression is controlled by FOXM1, see above [136]. 
p53/p21: See Tables 2 and 3  
CDK1 and FLT3 mutations: 
An alternative pathway for activation of CDK1 is the constitutive activation by FLT3-ITD; this signaling can activate both 
ERK1/2 and CDK1 and these kinases can then phosphorylate the transcription factor C/EBPα; this phosphorylation will 
inhibit its transcriptional activity and thereby contribute to the differentiation block in these AML cells [127–129]. 
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• The mitotic checkpoint. Several regulators of the mitotic checkpoint show decreased levels in 
primary human AML cells and this weakens the mitotic checkpoint response [141–143]. Blinkin 
can also be a fusion partner with MLL in 11q23 translocations; this fusion molecule seems to cause 
a dominant negative effect over the wild type protein.  
• Chromatin modeling. 11q23 translocations resulting in a fusion protein with septin cause disturbed 
chromatin remodeling [144]. The chromatin-modifying enzyme MLL5 can also be deleted [145,146] 
thereby altering the mitotic entry.  
• Aurora kinases and PLK1. The Aurora kinases [147–149] as well as PLK1 [137,139,150] can all be 
overexpressed in primary human AML cells and contribute to disturbances in mitotic entry, 
progression and/or exit.  
• The t(8;21) abnormality. This AML-associated abnormality can also disturb this step through 
downregulation of securin. Furthermore, cyclin B is involved in regulation of mitosis and can be 
downregulated by the fusion protein encoded by the t(8;21) fusion gene [141]. 
• CDK1 and FLT3 mutations. An alternative pathway for activation of CDK1 is constitutive 
activation of FLT3-initiated signaling by FLT3-ITD; this signaling can activate both ERK1/2 and 
CDK1 and these kinases then phosphorylate the transcription factor C/EBPα; this phosphorylation 
will inhibit its transcriptional activity and thereby contribute to the differentiation block in these 
AML cells [127–129]. Whether this phosphorylation is mediated by ERK1/2 or CDK1 seems to 
differ between patients [127,151], and this difference between FLT3-ITD patients may depend on 
the large variation of the ITDs between patients [152]. Thus, the FLT3-ITD abnormalities can alter 
both differentiation and cell cycle regulation through their effects on CDK1. 
5.5. Conclusions—Patients are Heterogeneous with Regard to Cell Cycle Regulation of the AML Cells  
The summaries given above and the data presented in Tables 2–4 clearly illustrate the patient 
heterogeneity with regard to cell cycle regulation in their AML cells. This heterogeneity is caused both 
by direct effects of the AML-associated genetic abnormalities (e.g., fusion proteins), but also by 
altered intracellular levels of important cell cycle regulators. Thus, the biological context of CDC25 in 
primary AML cells will differ between patients. These observations further support our hypothesis that 
the effect of CDC25 inhibition in primary human AML cells will differ between patients, and future 
biological as well as clinical studies therefore have to address the question whether CDC25 inhibition 
is effective for most or only a subset of AML patients.  
6. CDC25 Inhibition in the Treatment of Human AML 
6.1. CDC25 and the Anticancer Effects of mTOR Inhibition 
Inhibition of the PI3K-Akt-mTOR pathway is now considered for the treatment of human  
AML [89]. However, a recent study described that the mTOR inhibitor rapamycin affected the 
phosphorylation status of 250 phosphorylation sites in 161 cellular proteins, including several kinases 
and phosphatases [61]. These authors described that rapamycin-induced activation/phosphorylation of 
both CDC25B and Akt; silencing of the CDC25 phosphatase through mutation of the phosphorylation 
site then blocked the activation of Akt in various cancer cell lines. This last observation indicates that 
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phosphorylation of CDC25B is critical for the rapamycin-induced activation of Akt and eIF4E 
pathways while still suppressing the phosphorylation of the downstream mTOR targets p70S6K and 
4E-BPI [153]. The CDC25B-mediated activation of Akt/eIF4E may then represent a resistance 
mechanism against therapeutic inhibition of mTOR, and combined inhibition of PI3K-Akt-mTOR and 
CDC25 may then be a strategy to increase the anticancer effect of PI3K-Akt-mTOR inhibition. To the 
best of our knowledge these effects have only been described for rapamycin, and it is not known 
whether similar effects are seen for other mTOR inhibitors or for inhibitors targeting other members of 
this pathway. 
Our recent observation that resistance against PI3K/mTOR inhibitors in primary human AML cells 
was associated with increased mRNA expression of CDC25B also supports the hypothesis that CDC25 
inhibition will increase the anticancer effects of PI3K/mTOR inhibition, but at least for AML this 
combined strategy showed an increased efficiency only for certain patients [89].  
To summarize, the PI3K-Akt-mTOR pathway seems to be closely linked to CDC25, especially the 
CDC25A and CDC25B isoforms in human AML (Table 1), but our present knowledge is fragmentary 
and cannot explain all the experimental observations. CDC25A seems necessary for Akt-dependent 
and integrin-initiated proliferation (only examined in a limited number of cell lines), but at the same 
time signaling through this pathway can inhibit CDC25 through its sequestering in the cytoplasm. On 
the other hand, high constitutive CDC25B expression has been associated with resistance to PI3K and 
mTOR inhibitors in primary AML cells. Possible explanations for these apparent discrepancies could 
be that: (i) PI3K-Akt-mTOR signaling can be modulated by the crosstalk with other pathways; (ii) the 
final effect of CDC25 in primary human AML cells depends on the CDC25 level; and (iii) the 
observed effects in a limited number of AML cell lines may not be representative for primary human 
AML cells in general.  
6.2. CDC25 and Induction of Differentiation in AML Cells 
AML is characterized by accumulation of immature leukemia cells; these cells have a block in their 
differentiation but for some patients morphological signs of differentiation can be seen [154]. The 
function of CDC25 also seems to be affected by AML cell differentiation, i.e., to differ between AML 
cells with no signs of differentiation and cells showing monocytic differentiation [49]. Similarly, 
CDC25 is downregulated when the monocytic AML cell line ML-1 is stimulated to differentiate 
towards granulocytes in vitro [155]. However, it is not known whether the limited signs of 
differentiation seen for primary AML cells will have any major impact on the level of CDC25 or the 
effects of CDC25 inhibition in vivo.  
7. The Possible Use of CDC25 Inhibitors in the Treatment of human AML 
7.1. AML is a Heterogeneous Disease—the Possible Use of CDC25 Inhibitors Only in Subsets  
of Patients 
AML patients are classified according to the recently published WHO classification [154], and this 
classification is based on differences in morphology, predisposition (AML secondary to 
myelodysplastic syndromes (MDS) or chemotherapy), and the detection of defined genetic 
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abnormalities. Even by using only this limited number of parameters it is possible to classify the 
patients into a wide range of subsets that only reflects a part of the biological heterogeneity in human 
AML. Firstly, even though AML is generally defined as a disease with at least 20% leukemic blasts 
among bone marrow nucleated cells, there are exceptions from this definition, the most important 
being that patients with certain low-risk genetic abnormalities (i.e., inv(16), t(16;16), t(8;21)) are 
defined to have AML even when the number of blasts is <20%. Secondly, the age of the patient seems 
to reflect biological differences independent of the WHO classification. Thirdly, both the cytogenetic 
and molecular genetic abnormalities show a much more extensive heterogeneity than reflected in the 
WHO classification. Finally, a large number of differences at the protein level has also been  
detected [107,156,157]. In our opinion it would not be surprising if CDC25 inhibitors would be 
effective only for a subset of these highly heterogeneous patients. Future studies should therefore try to 
identify biomarkers for susceptibility to CDC25 inhibition.  
7.2. Combined Targeting of Cell Cycle Regulation—the Possible Combination of CDC25 Inhibition 
with Inhibitors of PLKs, AURORA Kinases or CDK Inhibitors 
Targeting of cell cycle regulation is already considered for the treatment of human AML, and 
especially inhibition of Aurora kinases or PLK1 has been studied in clinical trials as described in detail 
in a recent review [139]. These clinical studies have included hundreds of patients and both specific 
and multikinase inhibitors have been tried. The inhibitors are effective and partial responses or stable 
disease have been observed even for patients with advanced or multiresistant AML. Both PLK1 and 
Aurora B interact and activate CDC25 (Figure 3), and the clinical experience with these alternative cell 
cycle inhibitors suggests that CDC25 inhibition is effective in human AML.  
The 11q23 chromosomal abnormalities involving the H3K4 methyltransferase MLL give rise to an 
aggressive subtype of AML [154]. A recent study described that AML cells driven by MLL-AF9 
derived from t(9;11) are exceptionally reliant on CDK6 but not its functional homolog CDK4, and that 
the growth inhibition induced by CDK6 depletion is mediated through enhanced myeloid 
differentiation [158]. CDK6 seems to have a similar function also for other translocations involving 
11q23. The same seems to be true in acute lymphoblastic leukemia with 11q23 fusion genes [159]. 
CDK6 inhibition by the combined CDK4/6-inhibitor PD0332991 seems to have similar effects [159]. 
CDC25 is a regulator of the CDK4/CDK6/cyclin D complex (Figure 2), and the possible use of CDC25 
inhibitors alone or in combination with CDK targeting treatment should therefore be further explored.  
The sulfonamide derivative E7070/indisulam [160–162] inhibits carbonic anhydrases I, II, IV and 
IX [160]. This agent was originally identified as an antitumor agent due to its inhibitory effects on cell 
cycle progression in human cancer cell lines, including (i) suppression of cyclin E expression;  
(ii) reduced protein expression of cyclin A, cyclin B, CDK1 and CDK2; (iii) inhibition of CDK2 and 
Rb phosphorylation; and (iv) induction of p53 and p21 [160]. E7070 thereby disrupted cell cycle 
progression at different steps including G1/S and G2/M transitions. Combination of E7070 and CDC25 
inhibition would thus represent an extensive inhibition of several steps in the cell cycle together with 
inhibition of adaptation to the hypoxic bone marrow microenvironment of human AML [163–165].  
E7070 has been investigated in a recently reported clinical trial [166]. The study included 20 
patients with advanced or chemoresistant AML; patients were initially treated with E7070 alone and, if 
Molecules 2014, 19 18433 
 
 
no response, they received E7070 plus idarubicin and cytarabine. No patient responded to E7070 
alone, but eight patients achieved hematological remission after combination therapy. Two patients 
had prolonged marrow hypoplasia exceeding 42 days, the only grade ≥3 nonhematological toxicity 
was hyperbilirubinemia. The results are encouraging, but this was only an interim analysis and one has 
to await the final report. 
7.3. Combination of CDC25 Inhibitors with Conventional Chemotherapy 
PLK/Aurora kinase inhibitors seem to enhance the antileukemic effect of several cytotoxic drugs 
used in the clinical treatment of human AML, including cytarabine, daunorubicin and etoposide [139]. 
Furthermore, many cell cycle inhibitors show minimal cross-resistance with conventional anticancer 
agents [139]. This may also be true for CDC25 inhibitors, and the possibility to combine CDC25 
inhibitors with conventional antileukemic drugs should be further investigated in experimental studies 
and, eventually, in later clinical studies. 
One possibility would be to combine CDC25 inhibitors with intensive chemotherapy to increase the 
antileukemic effect and thereby improve the long-term AML-free survival. However, an alternative 
strategy could be to combine CDC25 inhibitors with low-toxicity disease-stabilizing strategies in patients 
that are unfit for the intensive and potentially curative treatment. If this last strategy is considered, 
CDC25 inhibitors may be combined with all-trans-retinoic acid (ATRA) plus valproic acid [167],  
low-dose cytarabine [168], hydroxyurea and/or 6-mercaptopurine [167–171].  
7.4. Toxicity versus Antileukemic Efficiency 
Several side effects have been observed with other pharmacological agents targeting cell cycle 
regulation [139]. Hematological toxicity with neutropenia (eventually febrile neutropenia) and 
thrombocytopenia seems to be relatively common for Aurora kinase and PLK1 inhibitors. The 
preliminary experience also for other cell cycle inhibitors including ARQ-501 [81,82] is that anemia 
and eventually other signs of bone marrow toxicity are relatively common. Combination of different 
cell cycle-targeting strategies or cell cycle targeting together with intensive chemotherapy will 
possibly lead to more severe cytopenias. This problem may be less severe if CDC25 inhibition is tried 
as a part of the post-remission/consolidation treatment when disease-induced bone marrow failure is 
not present. Gastrointestinal toxicity due to severe mucositis is another severe problem in conventional 
AML treatment and such toxicity is also common and can even be dose-limiting for PLK/Aurora 
kinase inhibitors [139]. Gastrointestinal toxicity may also become a problem if conventional AML 
chemotherapy is combined with CDC25 inhibition. Thus, the toxicity has to be carefully evaluated if 
CDC25 inhibition is combined either with other cell cycle-targeting strategies or with conventional 
chemotherapy, even for low-dose disease-stabilizing chemotherapy.  
7.5. Inhibition of Several Therapeutic Targets through the Use of a Single CDC25 Inhibitor 
Most CDC25 inhibitors inhibit all three CDC25 isoforms, but the relative strength of inhibition for 
each of the three isoforms varies between inhibitory agents [5]. Further studies are needed to clarify 
whether any of the three isoforms is of particular biological importance in human AML.  
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CDC25 has its own network of interacting kinases (Table 5) [21,25,29,30,32,33,44,47,48,50,60–65,172]. 
Its activity is modulated by various kinases and at the same time CDC25 regulates the activity of 
several kinases. CDC25 inhibition thereby offers the possibility to target several intracellular 
regulators through inhibition of a single molecule. As described above, CDC25 even seems to 
contribute to the regulation of cytoplasmic signaling pathways. Only future studies can clarify whether 
this represents a possibility for enhanced antileukemic activity rather than a risk of severe toxicity, and 
studies in AML animal models will then be important [173,174].  
Table 5. CDC25 and the most important members of its interacting kinase network—an 
overview of kinases that activate CDC25 and kinases that are activated by  
CDC25 dephosphorylation. 
Upstream Events Affecting CDC25 Activation (See Also Figure 3) 
Akt/PKB [60,62–65] 
This pathway can be an upstream inhibitor of CDC25 through sequestering it in the 
cytoplasm, but at the same time CDC25A is necessary for Akt-initiated proliferation.  
MAP kinases [30] Negative regulator during cellular stress.  
CDK1/cyclin B [44] Activates CDC25B and CDC25C in a positive feedback loop. 
CDK2/cyclin E [21,29] Activates CDC25A in a positive feedback loop. 
PLK1 [44] Activates CDC25 and promotes mitosis; both direct and indirect activating effects. 
Aurora kinases [47,48] 
Activate CDC25s and promote mitosis; both direct and indirect activating effects via 
activation of PLK1.  
Wee1 and Myt1 kinases [33] Inhibition of CDC25s. 
CHK1 [50,172] 
Inactivates all three isoforms of CDC25; it also inhibits CDC25s indirectly, e.g., 
through PLK1 inhibition.  
CHK2 [50,172] 
Inactivates all three isoforms of CDC25; it also inhibits CDC25s indirectly, e.g., 
through PLK1 inhibition. 
CDK1 [30,32] 
CDK1/cyclin A is dephosphorylated by CDC25B in late S-phase. Dephosphorylation 
of CDK1/cyclin B by CDC25 is a rate-limiting step for transition from G2 to mitosis. 
CDK2 [25,30] 
Activated during several steps in the cell cycle. Associates with cyclin E during G1/S 
transition and cyclin A during S-phase. 
CDK4 [25] Important for entry into S phase. Associates with cyclin D. 
CDK6 [25] Important for entry into S phase. Associates with cyclin D. 
Akt/protein kinase B [61] Its phosphorylation can be regulated by CDC25B. 
8. Final Comments 
As outlined above, CDC25 inhibition can be achieved directly and indirectly through inhibition of 
its upstream signaling pathways or its interacting molecules. The direct inhibitors have not been 
investigated in clinical trials (or are in the early stages of clinical trials) and their pharmacokinetic 
properties have to be better characterized, but despite this they should be regarded as promising 
therapeutic agents in human AML because they offer the possibility to target several proteins, 
including various CDC25 isoforms as well as several kinases, through the administration of single 
pharmacological agents. Their possible use in AML treatment either as single drugs or in combination 
with other drugs should therefore be further investigated. The first step will then be a further 
characterization of the effects at the cellular level and especially in primary human AML cells and this 
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should be followed by studies in AML animal models [173,174] as a basis for the design of further 
clinical studies. 
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